Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
January 10 2023 - 10:15AM
Silo Pharma, Inc.
(Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
a progress update on its sponsored research study with the
University of California, San Francisco (UCSF) examining
psilocybin’s effect on inflammatory activity in humans. The
clinical study evaluates three populations of patients suffering
from Parkinson's disease, bipolar disorder, and chronic pain.
Eric Weisblum, Chief Executive Officer of Silo Pharma,
commented, “The UCSF research team is making progress on the
clinical trial. The data gathered from these studies could uncover
the role of inflammatory activity on such conditions as
Parkinson’s, Bipolar disorder and Chronic Pain. Utilizing
Psilocybin in this study in a regimented dosing pattern, we hope to
gain significant data both in mechanism of action and potential
biomarker for personalization of psilocybin therapy. The
targeted patient populations from the study could provide support
for the development and use of psilocybin as a therapeutic coupled
with our novel homing peptides and topical technology.”
For each patient population, the clinical studies involve
preparation therapy, two separate dosing sessions with psilocybin,
and integration therapy. At the Clinical & Translational
Science Institute (CTSI) at UCSF, four blood samples are collected
from each participant, one at baseline before treatment begins, one
at 24 hours post dosing for each dosing session, and one at a
30-day follow up. The research team is on track to complete
data collection from Parkinson's disease patients by the end of
February 2023. Data collection is expected to begin in early 2023
for the bipolar study, and in April 2023 for the chronic pain study
patients.
The Clinical & Translational Science Institute at the
University of California, San Francisco facilitates clinical and
translational research to improve patient and community health.
CTSI does this by providing infrastructure, services, and training
to enable research to be conducted more efficiently and
effectively, and in new ways. To advance its mission, the Institute
develops broad coalitions and partnerships at the local, regional
and national levels to enable a transformation of the research
environment.
About Silo Pharma Silo Pharma. Inc. is a
development-stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research for people
suffering from indications such as PTSD, Alzheimer’s disease, and
other rare neurological disorders. Silo’s mission is to identify
assets to license and fund the research which we believe will be
transformative to the well-being of patients and the healthcare
industry. For more information, visit www.silopharma.com.
Forward-Looking Statements All statements other
than statements of historical fact in this announcement are
forward-looking statements that involve known and unknown risks and
uncertainties and are based on current expectations and projections
about future events and financial trends that the Company believes
may affect its financial condition, results of operations, business
strategy, and financial needs. Investors can identify these
forward-looking statements by words or phrases such as "may,"
"will," "expect," "anticipate," "aim," "estimate," "intend,"
"plan," "believe," "potential," "continue," "is/are likely to" or
other similar expressions. The Company undertakes no obligation to
update forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company's filings with the SEC.
Contact 800-705-0120investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Sep 2023 to Sep 2024